(E)-5,5-bis(4-tert-butylphenyl)-N-(isoquinolin-5-yl)-2,4-pentadinenamide | 1002123-55-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (E)-5,5-bis(4-tert-butylphenyl)-N-(isoquinolin-5-yl)-2,4-pentadinenamide
• 英文别名: (E)-5,5-bis(4-tert-butylphenyl)-N-(isoquinolin-5-yl)-2,4-pentadienamide；(2E)-5,5-bis(4-tert-butylphenyl)-N-isoquinolin-5-ylpenta-2,4-dienamide
• CAS: 1002123-55-8
• 化学式: C₃₄H₃₆N₂O
• 分子量: 488.673
• InChiKey: ZGOQJDKKAYEBHE-XYOKQWHBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.2
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 (E)-5,5-bis(4-tert-butylphenyl)-N-(isoquinolin-5-yl)-2,4-pentadinenamide
  参考文献：
  名称：

  Discovery of Novel 5,5-Diarylpentadienamides as Orally Available Transient Receptor Potential Vanilloid 1 (TRPV1) Antagonists

  摘要：

  We have developed a novel and potent chemical series of 5,5-diphenylpentadienamides for targeting TRPV1 in vitro and in vivo. In this investigation, we examined a variety of replacements for the S-position of dienamides with the goal of addressing issues related to pharmacokinetics. Our data suggest that substitution with alkoxy groups on the phenyl ring at the S-position increases their ability to penetrate the blood brain barrier. This investigation culminated in the discovery of compound (R)-36b, which showed a good pharmacokinetic profile. In vivo, compound (R)-36b was found to be effective at reversing mechanical allodynia in rats in a dose-dependent manner, and it reversed thermal hyperalgesia in a model of neuropathic pain induced by sciatic nerve injury.

  DOI：

  10.1021/jm300101n

文献信息

• PENTADIENAMIDE DERIVATIVE
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2050734A1

  公开（公告）日：2009-04-22

  The present invention provides a pentadienamide derivative represented by the formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like; R3 represents a hydrogen atom or is combined together with R4 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; R4 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like, or is combined together with R3 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; and R5, R6, and R7 may be the same or different, and each represents a hydrogen atom or methyl) or a pharmaceutically acceptable salt thereof, and the like.

  本发明提供了一种由式(I)表示的戊二烯酰胺衍生物:(其中R1代表取代或未取代的芳基或取代或未取代的芳香族杂环基；R2代表取代或未取代的芳基、取代或未取代的芳香族杂环基、取代或未取代的杂环螺环基或类似物；R3代表氢原子或与R4及其相邻的氮原子结合形成取代或未取代的杂环基；R4代表取代或未取代的芳基、取代或未取代的芳香族杂环基、取代或未取代的杂环螺环基或类似物，或与R3及其相邻的氮原子结合形成取代或未取代的杂环基；R5、R6和R7可以相同也可以不同，每个代表氢原子或甲基)或其药学上可接受的盐等。
• PENTADIENAMIDE DERIVATIVES
  申请人：NAKASATO Yoshisuke

  公开号：US20090203667A1

  公开（公告）日：2009-08-13

  The present invention provides a pentadienamide derivative represented by the formula (I): (wherein R 1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R 2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like; R 3 represents a hydrogen atom or is combined together with R 4 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; R 4 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, or the like, or is combined together with R 3 and the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group; and R 5 , R 6 , and R 7 may be the same or different, and each represents a hydrogen atom or methyl) or a pharmaceutically acceptable salt thereof, and the like.

  本发明提供了一种由以下公式（I）表示的五二烯酰胺衍生物：（其中，R1代表取代或未取代的芳基或取代或未取代的芳香杂环基；R2代表取代或未取代的芳基，取代或未取代的芳香杂环基，取代或未取代的杂环螺环基或类似物；R3代表氢原子或与R4及其相邻的氮原子结合形成取代或未取代的杂环基；R4代表取代或未取代的芳基，取代或未取代的芳香杂环基，取代或未取代的杂环螺环基或类似物，或与R3及其相邻的氮原子结合形成取代或未取代的杂环基；R5、R6和R7可以相同也可以不同，每个代表氢原子或甲基）或其药学上可接受的盐等。
• Discovery of Novel 5,5-Diarylpentadienamides as Orally Available Transient Receptor Potential Vanilloid 1 (TRPV1) Antagonists
  作者：Osamu Saku、Hiroshi Ishida、Eri Atsumi、Yoshiyuki Sugimoto、Hiroshi Kodaira、Yoshimitsu Kato、Shiro Shirakura、Yoshisuke Nakasato

  DOI：10.1021/jm300101n

  日期：2012.4.12

  We have developed a novel and potent chemical series of 5,5-diphenylpentadienamides for targeting TRPV1 in vitro and in vivo. In this investigation, we examined a variety of replacements for the S-position of dienamides with the goal of addressing issues related to pharmacokinetics. Our data suggest that substitution with alkoxy groups on the phenyl ring at the S-position increases their ability to penetrate the blood brain barrier. This investigation culminated in the discovery of compound (R)-36b, which showed a good pharmacokinetic profile. In vivo, compound (R)-36b was found to be effective at reversing mechanical allodynia in rats in a dose-dependent manner, and it reversed thermal hyperalgesia in a model of neuropathic pain induced by sciatic nerve injury.